Philanthropic partnership launches new initiative tackling antimicrobial resistance, the third-leading cause of death globally, by fast-tracking discovery of new treatments

The Gates Foundation, Novo Nordisk Foundation, and Wellcome have launched the Gram-Negative Antibiotic Discovery Innovator (Gr-ADI), a $50 million investment to combat antimicrobial resistance (AMR) caused by specific bacteria. The initiative will function as a consortium where funders, research institutions, and industry partners collaborate to drive innovation in developing new drugs. The Gr-ADI is part of a $300 million global health research and development partnership, aiming to advance solutions to health challenges disproportionately affecting low- and middle-income countries.